▲ +35.75% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $105.91, with a high forecast of $129.00 and a low forecast of $45.00. The average price target represents a 35.75% upside from the last price of $78.02.
The current consensus among 9 contributing investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. It is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2015 and is based in New Haven, Connecticut.